Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by Metformin by Jang, Se-Kyeong et al.
RESEARCH Open Access
Inhibition of mTORC1 through ATF4-
induced REDD1 and Sestrin2 expression by
Metformin
Se-Kyeong Jang1,2, Sung-Eun Hong3, Da-Hee Lee1, Ji-Young Kim3, Ji Yea Kim1, Sang-Kyu Ye4, Jungil Hong2,
In-Chul Park1* and Hyeon-Ok Jin3*
Abstract
Background: Although the major anticancer effect of metformin involves AMPK-dependent or AMPK-independent
mTORC1 inhibition, the mechanisms of action are still not fully understood.
Methods: To investigate the molecular mechanisms underlying the effect of metformin on the mTORC1 inhibition,
MTT assay, RT-PCR, and western blot analysis were performed.
Results: Metformin induced the expression of ATF4, REDD1, and Sestrin2 concomitant with its inhibition of
mTORC1 activity. Treatment with REDD1 or Sestrin2 siRNA reversed the mTORC1 inhibition induced by metformin,
indicating that REDD1 and Sestrin2 are important for the inhibition of mTORC1 triggered by metformin treatment.
Moreover, REDD1- and Sestrin2-mediated mTORC1 inhibition in response to metformin was independent of AMPK
activation. Additionally, lapatinib enhances cell sensitivity to metformin, and knockdown of REDD1 and Sestrin2
decreased cell sensitivity to metformin and lapatinib.
Conclusions: ATF4-induced REDD1 and Sestrin2 expression in response to metformin plays an important role in
mTORC1 inhibition independent of AMPK activation, and this signalling pathway could have therapeutic value.
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Background
Metformin (1,1-dimethylbiguanide hydrochloride) be-
longs to the biguanide class of drugs and is a widely used
drug administered orally to treat type 2 diabetes mellitus
[1]. Epidemiological studies have demonstrated that met-
formin use is associated with decreased cancer incidence
and mortality in patients with diabetes [2, 3]. Further-
more, accumulating evidence suggests that metformin
exerts antitumour effects in many cancers [4–6]. How-
ever, the underlying molecular mechanism by which
metformin reduces tumour incidence and inhibits cancer
cell growth in vitro and in vivo has not been clearly elu-
cidated. The well-accepted mechanism of metformin ac-
tion is inhibition of mitochondrial respiratory complex I
and activation of AMP-activated protein kinase (AMPK)
in response to energy depletion [7]. AMPK is a heterodi-
meric protein complex that plays an essential role in
sensing energy and suppressing cell growth under low-
energy conditions [8]. Activated AMPK phosphorylates
multiple downstream targets to maintain cellular energy
homeostasis [8, 9].
One of the central downstream targets inhibited by
AMPK is mechanistic target of rapamycin complex 1
(mTORC1), a serine/threonine kinase that has a critical
role in controlling cell growth and cellular metabolism
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by integrating various environmental signals, such as
growth factors, amino acids, and glucose [10, 11].
mTORC1 directly phosphorylates downstream sub-
strates, including ribosomal S6 kinase 1 (S6K1) and
eukaryotic initiation factor 4E (eIF4E)-binding protein 1
(4E-BP1), to regulate protein synthesis to promote cell
proliferation [12]. mTORC1 is tightly regulated by mul-
tiple upstream pathways. The response of mTORC1 sig-
nalling to growth factors is mediated by the small
GTPase Ras homology enriched in brain (Rheb), which
is negatively regulated by tuberous sclerosis complex
(TSC1/2) proteins [13–15]. When the PI3K/Akt pathway
is activated by growth factors, Akt phosphorylates TSC2
and disrupts the TSC1/2 complex [16, 17]. Energy levels
signal to mTORC1 through AMPK by two mechanisms
[18]. Firstly, AMPK directly phosphorylates the TSC2 on
S1387 to activate TSC2 and promote inhibition of
mTORC1 inhibition through the Rheb axis [19, 20]. The
second, AMPK phosphorylates raptor on serines 722
and 792 to directly inhibit mTORC1 activity [21]. Some
studies have reported that metformin inhibits the
mTORC1 signalling pathway independent of AMPK ac-
tivation [22–24]. However, the molecular mechanisms
involved in AMPK-independent mTORC1 inhibition by
metformin have not been fully elucidated.
In the present study, we investigated the molecular
mechanism(s) by which metformin induces mTORC1
inhibition in non-small cell lung cancer (NSCLC) cells.
We found that inhibition of mTORC1 in response to
metformin requires ATF4 and that ATF4-induced up-
regulation of REDD1 and Sestrin2 is implicated in this
effect. REDD1 and Sestrin2 are necessary for mTORC1
inhibition by metformin treatment, and the response oc-
curs through an ATF4-dependent mechanism in NSCLC
cells. In conclusion, ATF4-induced REDD1 and Sestrin2
expression triggered by metformin plays an important role
in mTORC1 inhibition independent of AMPK activation.
Methods
Cell culture and reagents
H1299 NSCLC cells were obtained from ATCC (Manas-
sas, VA, USA) and cultured in RPMI 1640 medium
(#LM011–01; Welgene, Gyeongsangbuk-do, Republic of
Korea) supplemented with 10% foetal bovine serum
(Gibco; Thermo Fisher Scientific, Waltham, MA, USA).
Metformin, phenformin and thiazolyl blue tetrazolium
bromide (MTT) were purchased from Sigma-Aldrich
(Merck KGaA, Darmstadt, Germany).
Cell viability assay
Cell viability was assessed by measuring the mitochon-
drial conversion of MTT. The proportion of converted
MTT was calculated by measuring the absorbance at
570 nm. The results are expressed as the percentage
reduction in MTT under the assumption that the ab-
sorbance of the control cells was 100%. The MTT exper-
iments were repeated three times.
RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR)
RNA was isolated from H1299 cells using TRIzol Re-
agent according to the manufacturer’s instructions (Invi-
trogen; Thermo Fisher Scientific). cDNA primed with
oligo dT was prepared from 2 μg total RNA using M-
MLV Reverse Transcriptase (Invitrogen; Thermo Fisher
Scientific).
The following specific primers were used for PCR:
ATF4: 5′-AGTCGGGTTTGGGGGCTGAAG − 3′ and
5′-TGGGGAAAGGGGAAGAGGTTGTAA-3′, 437 bp
product; β-actin: 5′-GGATTCCTATGTGGGCGACAG-
3′ and 5′-CGCTCGGTGAGGATCTTCATG-3′, 438 bp
product. The PCR products were visualized on a 2%
agarose gel containing ethidium bromide.
Real-time PCR
Real-time PCR was conducted using TaqMan Gene Ex-
pression Assay Probes (Applied Biosystems, Foster City,
CA, USA) for mRNA quantification of Redd1 (assay ID:
Hs01111681_g1), Sestrin1 (assay ID: Hs00902782_m1),
Sestrin2 (assay ID: Hs00230241_m1), and Sestrin3 (assay
ID: Hs00914870_m1). β-actin (assay ID: Hs01060665_
g1) was used as an internal control. Quantitative real-
time PCR was performed using an ABI 7500 Real-Time
PCR System (Applied Biosystems). The fold change in
gene expression was determined using the comparative
CT (2–ΔΔCT) method.
Transient transfection
ATF4 (#sc-35,112), REDD1 (#sc-45,806), Sestrin2 (sc-106,
544) and control (#sc-37,007) siRNAs were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA). siRNA
transfections in H1299 cells were performed using
Lipofectamine RNAiMAX according to the manufacturer’s
instructions (Invitrogen; Thermo Fisher Scientific).
Western blot analysis
Proteins from cell lysates were separated using 6–11%
sodium dodecyl sulphate-polyacrylamide gels and trans-
ferred to nitrocellulose membranes followed by im-
munoblotting with the specified primary and
horseradish peroxidase-conjugated secondary antibodies.
The following antibodies were used: S6K (#9202), p-S6K
(Thr389) (#9205), 4E-BP1 (#9644), ACC (#3662), p-ACC
(Ser79) (#3661), AMPKα (#2532), and p-AMPKα
(Thr172) (#2535) were obtained from Cell Signaling
Technology. The ATF4 (#sc-200) antibody was obtained
from Santa Cruz Biotechnology. The REDD1 (#10638–
1-AP), Sestrin1 (#21668–1-AP), Sestrin2 (#10795–1-AP),
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and Sestrin3 (#11431–2-AP) antibodies were obtained
from the Proteintech Group (Chicago, IL, USA), and the
β-actin (#A5316) antibody was obtained from Sigma-
Aldrich (Merck KGaA).
Statistical analysis
Data are expressed as the mean ± standard deviation (SD)
of three independent experiments. Statistical analysis was
performed using one-way analysis of variance followed by
Tukey’s post hoc test with the GraphPad Prism software
(Version 5.0; GraphPad Software Inc., San Diego, CA,
USA). P < 0.05, P < 0.01 and P < 0.001 were considered to
indicate statistically significant results.
Results
Metformin induces mTORC1 inhibition through AMPK
activation
We first investigated the impact of metformin on
mTORC1 activity in NSCLC cells. H1299 cells were
treated with metformin at the above mentioned concen-
trations for 24 h. As shown in Fig. 1A, metformin inhib-
ited mTORC1 activity, as shown by the decrease in S6K
Fig. 1 Metformin inhibits mTORC1 through AMPK. (a) H1299 cells were treated with the indicated concentrations of metformin or phenformin for
24 h. (b) H1299 cells were transfected with control or AMPKα siRNA for 12 h and were then treated with 10 mM metformin for 24 h. (a, b) Data
are representative of two independent experiments. CTL: control
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phosphorylation. Phosphorylation of 4E-BP1 was de-
creased by metformin, as evidenced by a shift to faster-
migrating species [25]. Phenformin, a metformin
analogue also inhibited mTORC1 activity, as assessed by
reduced phosphorylation of S6K1 and 4E-BP1. It has
been reported that metformin requires AMPK to inhibit
mTORC1 [26]. As expected, metformin and phenformin
both induced AMPK activation, as evaluated by the acti-
vating phosphorylation of Thr172 in AMPKα and Ser79
in the AMPK substrate acetyl-CoA carboxylase (ACC)
(Fig. 1A). Next, we explored the effect of the absence of
AMPK on metformin-induced mTORC1 inhibition.
AMPKα siRNA abrogated AMPKα expression and pre-
vented ACC phosphorylation induced by metformin treat-
ment (Fig. 1B). The metformin-induced decrease in phfv.
osphorylated S6K was restored by knockdown of
AMPKα (Fig. 1B). These data suggest that AMPK activa-
tion contributes to mTORC1 inhibition in response to
metformin.
Metformin induces mTORC1 inhibition through ATF4
It has been reported that metformin can also inhibit
mTORC1 through an AMPK-independent pathway [22–
24]. Since activation of the PERK-eIF2α-ATF4 axis was
triggered by metformin [27], we investigated whether
ATF4 is involved in metformin-induced mTORC1 inhib-
ition. Metformin induced ATF4 protein expression but
did not affect the induction of ATF4 mRNA (Fig. 2A-D).
The metformin-induced decrease in phosphorylated S6K
was restored by knockdown of ATF4 (Fig. 2E and F),
suggesting that ATF4 is necessary for metformin-
mediated inhibition of mTORC1.
REDD1 and Sestrin2 expression in the presence of
metformin is regulated by ATF4
We previously reported that ATF4 facilitates the tran-
scription of the REDD1 gene [28]. Thus, we investigated
whether REDD1 expression is upregulated by metformin-
induced ATF4 activation. Metformin and phenformin
both induced REDD1 protein and mRNA expression in a
dose-dependent manner (Fig. 3A and B). ATF4 siRNA al-
most completely blocked the upregulation of REDD1 in
the presence of metformin (Fig. 3C and D). Sestrins are
stress-inducible proteins that regulate metabolic homeo-
stasis [29]. We investigated whether Sestrins are upregu-
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Fig. 2 Metformin inhibits mTORC1 through ATF4. (a, b) H1299 cells were treated with the indicated concentrations of metformin for 24 h. (c, d)
H1299 cells were treated with 10 mM metformin for the indicated time. The protein levels (a, c) and mRNA levels (b, d) were estimated by
western blot and RT- PCR analysis, respectively. (a-d) Data are representative of two independent experiments. (e, f) H1299 cells were transfected
with control or ATF4 siRNA for 12 h and were then treated with 10 mM metformin for 24 h. (e) Data are representative of three independent
experiments. (f) The p-S6K expression was quantified using ImageJ software and fold change with respect to control after normalization to
respective S6K bands was plotted as histogram. (n = 3; ***P < 0.001; NS, not significant). CTL: control
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and F, Sestrin2 protein and mRNA levels were upregu-
lated under metformin or phenformin treatment. How-
ever, metformin and phenformin had no impact on the
gene or protein expression of Sestrin1 or Sestrin3. We fur-
ther investigated whether ATF4 is responsible for the up-
regulation of Sestrin2 expression in response to
metformin. H1299 cells were transfected with ATF4
siRNA and treated with metformin. ATF4 siRNA blocked
the upregulation of Sestrin2 in response to metformin
(Fig. 3C and D). These data suggest that ATF4 activation
is important for the induction of REDD1 and Sestrin2 ex-
pression by metformin treatment.
AMPK and ATF4 do not affect each other’s expression in
the presence of metformin
We investigated whether AMPK and ATF4 affect each
other’s expression in the presence of metformin. We
first investigated the protein expression of ATF4 and its
downstream targets REDD1 and Sestrin2 by treatment
with metformin in AMPK knockdown cells. The
downregulation of AMPKα did not alter the induction
of ATF4, REDD1 or Sestrin2 expression by metformin
(Fig. 4A). Next, we investigated AMPK activation by
metformin in cells with knockdown of ATF4 and its
downstream targets REDD1 and Sestrin2. H1299 cells
were transfected with ATF4, REDD1 and Sestrin2 siR-
NAs and then treated with metformin. Metformin-
induced AMPKα and ACC phosphorylation was not
changed by siRNAs against ATF4, REDD1 or Sestrin2
(Fig. 4B-D). These data suggest that AMPK and ATF4
do not affect each other’s expression in response to
metformin.
REDD1 and Sestrin2 expression induced by metformin is
involved in mTORC1 inhibition
We investigated whether REDD1 and/or Sestrin2 induc-
tion by metformin suppresses mTORC1 activity. As
shown in Fig. 5A-C, the decreased phosphorylation of
S6K by metformin was recovered in cells treated with
REDD1 siRNA or Sestrin2 siRNA. Silencing both
(See figure on previous page.)
Fig. 3 Metformin induces the expression of REDD1 and Sestrin2 in an ATF4-dependent manner. (a, b, e, f) H1299 cells were treated with the
indicated concentrations of metformin or phenformin for 24 h. (c, d) H1299 cells were transfected with control or ATF4 siRNA for 12 h and were
then treated with 10mM metformin for 24 h. The protein levels (a, c, e) and mRNA levels (b, d, f) were estimated by western blot and real-time
PCR analysis, respectively. (a, c, e) The western blot is representative of two independent experiments. (b, d, f) The real-time PCR results for each
sample were analysed according to the 2−ΔΔCt method using β-actin as the internal control. Gene transcription is presented as the fold change
relative to the control sample (n = 3; ***P < 0.001). CTL: control, SESN1: Sestrin1, SESN2: Sestrin2, SESN3: Sestrin3
Fig. 4 AMPK and ATF4 do not affect each other’s expression under metformin treatment. (a–d) H1299 cells were transfected with control, AMPKα,
ATF4, REDD1, or Sestrin2 siRNA for 12 h and then treated with 10mM metformin for 24 h. The indicated protein levels were estimated by western
blot analysis. The blot is representative of two independent experiments. CTL: control, SESN2: Sestrin2
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REDD1 and Sestrin2 further attenuated the effect of
metformin on the inhibition of S6K phosphorylation.
Interestingly, compared with that in the control siRNA-
treated cells, the metformin-induced Sestrin2 expression
was higher in the REDD1 siRNA-treated cells (Fig. 5A
and D), and the metformin-induced REDD1 expression
was higher in the Sestrin2 siRNA-treated cells (Fig. 5B
and E). These data suggest that REDD1 and Sestrin2 are







































































































































































Fig. 5 Metformin-induced REDD1 and Sestrin2 expression is involved in mTORC1 inhibition by metformin. (a-e) H1299 cells were transfected with
control, REDD1, Sestrin2, or REDD1/Sestrein2 siRNA for 12 h and then treated with 10mM metformin for 24 h. (a, b, c) The indicated protein levels were
estimated by western blot analysis. (upper panels; a, b, c) The blot is representative of three independent experiments. (bottom panels; a, b, c) The p-
S6K protein expression was quantified using ImageJ software and fold change with respect to control after normalization to respective S6K protein
bands was plotted as histogram (n = 3; ***P < 0.001; ns, not significant). (d, e) The indicated mRNA levels were estimated by real-time PCR analysis. The
real-time PCR results for each sample were analysed according to the 2−ΔΔCt method using β-actin as the internal control. Gene transcription is
presented as the fold change relative to the control sample (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). CTL: control, SESN2: Sestrin2
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Lapatinib enhances cell sensitivity to metformin, and
knockdown of REDD1 and Sestrin2 decreases cell sensi-
tivity to metformin and lapatinib.
Next, we investigated the effect of metformin on
H1299 cell viability. A less than 25% decrease in cell via-
bility was observed in H1299 cells treated with 10 mM
metformin for 24 h (Fig. 6A). The combination of kinase
inhibitor and biguanide has been reported to have in-
creased antitumour efficacy [30], and we investigated
whether lapatinib, a dual EGFR and HER2 kinase inhibi-
tor, enhances cell sensitivity to metformin. Interestingly,
lapatinib potentiated the metformin’s effect on the
ATF4, REDD1, and Sestrin2 expression and the AMPK
phosphorylation (Fig. 6B). Lapatinib enhanced the
metformin-induced inhibition of S6K phosphorylation
and the inhibitory effect of metformin on the cell viabil-
ity (Fig. 6B and C). To investigate whether REDD1 and
Sestrin2 are involved in cell sensitivity to lapatinib and
metformin, we knocked down REDD1 and Sestrin2 in
H1299 cells, followed by lapatinib and metformin treat-
ment. siRNA silencing of both REDD1 and Sestrin2 ab-
rogated REDD1 and Sestrin2 expression but did not
affect AMPKα phosphorylation induced by metformin
treatment (Fig. 6D). Treatment with REDD1 and Ses-
trin2 siRNA significantly increased viability in cells
treated with metformin and lapatinib, suggesting that ex-
pression of both REDD1 and Sestrin2 is involved in cell
sensitivity to metformin and lapatinib (Fig. 6E). Next, we
knocked down ATF4 in H1299 cells, followed by lapati-
nib and metformin treatment to investigate whether
ATF4 is involved in cell sensitivity to lapatinib and met-
formin. siRNA-mediated knockdown of ATF4 abrogated
the expression of ATF4 and its downstream targets
REDD1 and Sestrin2 induced by metformin (Fig. 6F).
However, ATF4 siRNA did not affect metformin-
induced AMPKα phosphorylation (Fig. 6F). ATF4 siRNA
significantly increased viability in cells treated with met-
formin and lapatinib (Fig. 6G). These results suggest that
ATF4-mediated REDD1 and Sestrin2 expression is in-
volved in cell sensitivity to metformin and lapatinib.
Discussion
In the present study, we provide evidence that metfor-
min inhibited mTORC1 signalling independent of
AMPK. We found that metformin inhibited mTORC1
signalling via ATF4-induced REDD1 and Sestrin2 ex-
pression. Furthermore, we demonstrated that treatment
with a combination of metformin and lapatinib signifi-
cantly reduced the viability of NSCLC cells. siRNAs tar-
geting REDD1 and Sestrin2 significantly increased
viability in cells treated with metformin and lapatinib.
Our study advances the current understanding of the
molecular mechanism used by metformin to regulate
mTORC1 pathways as a cancer therapy.
Metformin treatment induced AMPK activation and
mTORC1 inhibition (Fig. 1A). It has been reported that
metformin requires AMPK to inhibit mTORC1 [26]. In
this study, we found that metformin-induced AMPK acti-
vation contributed to mTORC1 inhibition. However,
downregulation of AMPK did not fully recover metformin-
induced mTORC1 inhibition (Fig. 1B). This result suggests
that there are additional mechanisms involved in the
metformin-mediated inhibition of mTORC1.
REDD1 is one of the best characterized suppressors of
mTORC1. REDD1 promotes the association of PP2A
with PKB/Akt, ultimately leading to TSC2 activation and
mTORC1 inhibition [31]. Sestrin2 has also been re-
ported to inhibit mTORC1 signalling via activation of
AMPK [32, 33]. More recently, Sestrin2 was proposed to
inhibit mTORC1 through modulation of GATOR com-
plexes [34, 35]. In this study, we found that mTORC1
was partially suppressed by metformin-induced expres-
sion of REDD1 or Sestrin2 (Fig. 5A and B). These data
suggest that induction of either REDD1 or Sestrin2 alone
by metformin cannot completely inhibit mTORC1, and
REDD1 and Sestrin2 act together to inhibit mTORC1
following metformin treatment. Interestingly, when
compared with control siRNA-treated cells, it was ob-
served that metformin-induced Sestrin2 expression was
more elevated in REDD1 siRNA-treated cells, and
metformin-induced REDD1 expression was more ele-
vated in Sestrin2 siRNA-treated cells. Further research is
needed to confirm in these findings.
It has been reported that metformin increases REDD1
expression in a p53-dependent manner [22]. Because the
H1299 cell line used in this study lacks p53, metformin-
induced REDD1 expression may be p53-independent. It
has been reported that activation of the PERK-eIF2α-
ATF4 axis is triggered by metformin [27], and upregula-
tion of REDD1 and Sestrin2 by leucine deprivation is
mediated by ATF4 [36]. We found that REDD1 and Ses-
trin2 induced by metformin are mediated by ATF4. Fur-
thermore, we showed that siRNA targeted against ATF4,
REDD1, and Sestrin2 did not change the AMPK activa-
tion induced by metformin. Additionally, AMPKα siRNA
did not change ATF4-induced REDD1 and Sestrin2 ex-
pression. These data suggest that ATF4-induced
mTORC1 inhibition by metformin occurs independent
of AMPK activation.
The combination of kinase inhibitor and biguanide has
been reported to have increased antitumour efficacy
[30]. Lapatinib, a dual EGFR and HER2 kinase inhibitor,
enhanced the metformin’s effect on the ATF4, REDD1,
and Sestrin2 expression and the inhibitory effects of
metformin on the viability of H1299 cells. In cells with
reduced viability due to combined metformin/lapatinib
treatment, treatment with ATF4 siRNA or REDD1/Ses-
trin2 siRNA significantly increased viability, indicating





































































































Fig. 6 (See legend on next page.)
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that ATF4-mediated REDD1 and Sestrin2 expression is
involved in cell sensitivity to metformin and lapatinib.
In conclusion, ATF4-mediated REDD1 and Sestrin2
expression triggered by metformin plays an important
role in mTORC1 inhibition independent of AMPK acti-
vation, and this signalling pathway could have thera-
peutic value.
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